Richard Pzena
Pzena Investment Management
Richard Pzena USANA Health Sciences Inc stake
total: 584
Pzena Investment Management USNA trades
- Total transactions:
- 20
- New positions:
- 1
- Added:
- 11
- Reduced:
- 8
- Held since:
- 2021 Q3
- Held for:
- 20 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Richard Pzena holds 1,205,587 USANA Health Sciences Inc (USNA) shares with a market value of roughly $25.74M accounting for 0.08% of the overall portfolio. To date, the estimated cost basis is nearly $67.44 for "buy" trades and estimated average "sell" price is $35.95. Pzena Investment Management first purchased USNA in 2021 Q3, initially acquiring 95,708 shares. Since the initial investment in USANA Health Sciences Inc (USNA), Pzena Investment Management has made 19 more transactions.
When did Richard Pzena buy USANA Health Sciences Inc (USNA)?
Richard Pzena first invested in USANA Health Sciences Inc (USNA) in 2021 Q3 at the reported quarter-end price of $92.20 per share.
What's the cost basis of Pzena Investment Management's USNA stake?
The estimated cost basis for USANA Health Sciences Inc (USNA) stake is around $67.44 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $67.44
- Weighted AVG sell price:
- $35.95
Richard Pzena's historical trades in USANA Health Sciences Inc
20 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.08%
|
1,205,587
|
$21.35
|
$25,739,282
|
+8.72% (+96,654)
|
+0.01%
|
|
2026 Q1
|
0.06%
|
1,108,933
|
$17.47
|
$19,373,060
|
-2.25% (-25,496)
|
-0%
|
|
2025 Q4
|
0.07%
|
1,134,429
|
$19.63
|
$22,268,841
|
-6.45% (-78,159)
|
-0%
|
|
2025 Q3
|
0.11%
|
1,212,588
|
$27.55
|
$33,406,799
|
+1.20% (+14,328)
|
+0%
|
|
2025 Q2
|
0.12%
|
1,198,260
|
$30.53
|
$36,582,878
|
+9.41% (+103,074)
|
+0.01%
|
|
2025 Q1
|
0.10%
|
1,095,186
|
$26.97
|
$29,537,166
|
+0.75% (+8,110)
|
+0%
|
|
2024 Q4
|
0.13%
|
1,087,076
|
$35.89
|
$39,015,158
|
+3.57% (+37,466)
|
+0%
|
|
2024 Q3
|
0.13%
|
1,049,610
|
$37.92
|
$39,801,211
|
+7.47% (+72,977)
|
+0.01%
|
|
2024 Q2
|
0.16%
|
976,633
|
$45.24
|
$44,182,877
|
+24.36% (+191,289)
|
+0.03%
|
|
2024 Q1
|
0.13%
|
785,344
|
$48.50
|
$38,089,184
|
+3.12% (+23,729)
|
+0%
|
|
2023 Q4
|
0.15%
|
$53.60
|
-3.28% (-25,824)
|
|||
|
2023 Q3
|
0.20%
|
$58.61
|
-0.33% (-2,606)
|
|||
|
2023 Q2
|
0.21%
|
$63.04
|
-3.46% (-28,339)
|
|||
|
2023 Q1
|
0.22%
|
$62.90
|
+14.16% (+101,503)
|
|||
|
2022 Q4
|
0.17%
|
$53.20
|
-0.65% (-4,654)
|
|||
|
2022 Q3
|
0.20%
|
$56.05
|
-0.57% (-4,116)
|
|||
|
2022 Q2
|
0.24%
|
$72.36
|
-1.13% (-8,288)
|
|||
|
2022 Q1
|
0.22%
|
$79.45
|
+64.70% (+288,307)
|
|||
|
2021 Q4
|
0.17%
|
$101.20
|
+365.62% (+349,924)
|
|||
|
2021 Q3
|
0.03%
|
$92.20
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.